Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $32.2 million.

  • OptimizeRx's Receivables - Net rose 2241.05% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 2241.05%. This contributed to the annual value of $38.2 million for FY2024, which is 540.37% up from last year.
  • Latest data reveals that OptimizeRx reported Receivables - Net of $32.2 million as of Q3 2025, which was up 2241.05% from $33.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Receivables - Net ranged from a high of $38.2 million in Q4 2024 and a low of $757218.0 during Q3 2021
  • Over the past 5 years, OptimizeRx's median Receivables - Net value was $20.8 million (recorded in 2023), while the average stood at $20.6 million.
  • In the last 5 years, OptimizeRx's Receivables - Net tumbled by 9432.05% in 2021 and then skyrocketed by 225252.04% in 2022.
  • Over the past 5 years, OptimizeRx's Receivables - Net (Quarter) stood at $24.8 million in 2021, then decreased by 10.67% to $22.2 million in 2022, then skyrocketed by 63.63% to $36.3 million in 2023, then increased by 5.4% to $38.2 million in 2024, then dropped by 15.66% to $32.2 million in 2025.
  • Its Receivables - Net was $32.2 million in Q3 2025, compared to $33.5 million in Q2 2025 and $32.7 million in Q1 2025.